
Neurocrine Biosciences NBIX
$ 158.42
-0.4%
Quarterly report 2026-Q1
added 05-05-2026
Neurocrine Biosciences ROA Ratio 2011-2026 | NBIX
Annual ROA Ratio Neurocrine Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.33 | 9.18 | 7.68 | 6.52 | 4.32 | 23.48 | 2.83 | 2.13 | -17.43 | -38.65 | -18.73 | -24.91 | -29.8 | 2.56 | 27.15 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 27.15 | -38.65 | -2.22 |
Quarterly ROA Ratio Neurocrine Biosciences
| 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.78 | 6.65 | 10.32 | 9.52 | 6.89 | 9.81 | 9.05 | 10.74 | 3.33 | 6.52 | 6.8 | 3.79 | 4.49 | 5.61 | 2.88 | 5.04 | 5.02 | 25.07 | 20.64 | 23.06 | 23.48 | 6.03 | 13.47 | 12.81 | 2.83 | 2.05 | 3.04 | -1.48 | 2.13 | 1.15 | -5.32 | -12.06 | -17.43 | -30.51 | -39.25 | -42.95 | -38.65 | -32.59 | -29.74 | -23.76 | -18.73 | -20.56 | -19.84 | -20.29 | -24.91 | -23.79 | -24.45 | -26.86 | -29.8 | -18.08 | -12.45 | -4.79 | 2.56 | -1.32 | 22.93 | 24.62 | 27.15 | 22.68 | 1.43 | 2.08 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.15 | -42.95 | -2.74 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
-241.53 | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M | ||
|
Coherus BioSciences
CHRS
|
65.04 | $ 1.57 | -3.68 % | $ 184 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-22.19 | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 16.87 | -2.49 % | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
8.97 | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-24.26 | $ 7.47 | -4.6 % | $ 205 M | ||
|
Athira Pharma
ATHA
|
-114.6 | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40.14 | - | 0.74 % | $ 768 M | ||
|
Eton Pharmaceuticals
ETON
|
-4.99 | $ 30.26 | 1.0 % | $ 814 M | ||
|
Galera Therapeutics
GRTX
|
2071.28 | - | -32.59 % | $ 7.61 M | ||
|
Exelixis
EXEL
|
27.51 | $ 50.13 | -1.9 % | $ 13.6 B | ||
|
Fortress Biotech
FBIO
|
19.94 | $ 2.41 | 4.78 % | $ 67.2 M | ||
|
Midatech Pharma plc
MTP
|
-35.12 | - | -18.52 % | $ 27.3 M | ||
|
Forte Biosciences
FBRX
|
-83.81 | $ 23.11 | -3.55 % | $ 299 M | ||
|
AbCellera Biologics
ABCL
|
-10.79 | $ 4.09 | -7.05 % | $ 1.22 B | ||
|
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.63 | 2.52 % | $ 434 M | ||
|
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - | ||
|
BioNTech SE
BNTX
|
-5.17 | $ 89.55 | -2.65 % | $ 21.6 B | ||
|
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | ||
|
Galectin Therapeutics
GALT
|
-157.87 | $ 2.17 | -7.66 % | $ 139 M | ||
|
Celyad Oncology SA
CYAD
|
-207.62 | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
-43.36 | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
-56.95 | - | - | $ 344 M | ||
|
IMV
IMV
|
-121.19 | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | ||
|
Gilead Sciences
GILD
|
14.42 | $ 129.58 | -1.88 % | $ 161 B | ||
|
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 3.36 | -3.72 % | $ 5.53 M | ||
|
Aeterna Zentaris
AEZS
|
-48.33 | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
53.1 | $ 0.72 | -1.58 % | $ 32.9 M | ||
|
Esperion Therapeutics
ESPR
|
-4.87 | $ 3.12 | - | $ 649 M | ||
|
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | ||
|
Genmab A/S
GMAB
|
17.12 | $ 26.54 | -1.34 % | $ 1.72 B | ||
|
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-119.89 | - | - | $ 28.6 M |